Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Bioscns (NQ: APTO )

0.6400 +0.0062 (+0.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 152,086
Open 0.6400
Bid (Size) 0.6202 (13)
Ask (Size) 0.6500 (9)
Prev. Close 0.6338
Today's Range 0.6220 - 0.6550
52wk Range 0.4255 - 1.550
Shares Outstanding 93,005,278
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
From Aptose Biosciences, Inc.
Via Globe NewsWire
Canaccord Genuity Maintains Buy Rating for Aptose Biosciences: Here's What You Need To Know
 
Via Benzinga

Performance

YTD
+6.67%
+6.67%
1 Month
+9.23%
+9.23%
3 Month
+10.34%
+10.34%
6 Month
+7.56%
+7.56%
1 Year
-52.94%
-52.94%

More News

Read More
Aptose Reports Results for the Fourth Quarter and Full Year 2022
From Aptose Biosciences, Inc.
Via Globe NewsWire
Preview: Aptose Biosciences's Earnings
Via Benzinga
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
From Aptose Biosciences, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Aptose Biosciences: Q2 Earnings Insights
Via Benzinga
Earnings Scheduled For March 23, 2023
Via Benzinga
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
From Aptose Biosciences, Inc.
Via Globe NewsWire
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
From Aptose Biosciences, Inc.
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
From Aptose Biosciences, Inc.
Via Globe NewsWire
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
From Aptose Biosciences, Inc.
Via Globe NewsWire
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
Via Benzinga
Aptose Biosciences Establishes New At-The-Market Facility
From Aptose Biosciences, Inc.
Via Globe NewsWire
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
From Aptose Biosciences, Inc.
Via Globe NewsWire
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
From Aptose Biosciences, Inc.
Via Globe NewsWire
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
From Aptose Biosciences, Inc.
Via Globe NewsWire
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
Via Benzinga
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
Via Benzinga
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
From Aptose Biosciences, Inc.
Via Globe NewsWire
Aptose Reports Results for the Third Quarter 2022
From Aptose Biosciences, Inc.
Via Globe NewsWire
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
From Aptose Biosciences, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.